Reliant Adds Antara To Cardiovascular Portfolio Following Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Antara (fenofibrate) clears FDA under Sec. 505(b)(2) NDA provision; it will compete with Abbott's Tricor to treat adult patients with primary hypercholesterolemia, mixed dyslipidemia, or hypertriglyceridemia. Abbott is developing a new formulation of Tricor.
You may also be interested in...
Reliant Launches Omacor With Existing Sales Force
Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.
Reliant Launches Omacor With Existing Sales Force
Reliant had hoped to hire 200 additional reps to support launch of the omega-3 product, which was approved in 2004.
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.